Diagnostic criteria and adjudication process both determine published event-rates: the ACTION trial experience.

Kirwan, Bridget-Anne; Lubsen, Jacobus; de Brouwer, Sophie; Danchin, Nicolas; Battler, Alexander; Bayes de Luna, Antonio; Dunselman, Peter H J M; Glasser, Stephen; Koudstaal, Peter J; Sutton, George; van Dalen, Frederik J; Poole-Wilson, Philip A

Kirwan, Bridget-Anne; Lubsen, Jacobus; de Brouwer, Sophie; Danchin, Nicolas; Battler, Alexander; Bayes de Luna, Antonio; Dunselman, Peter H J M; Glasser, Stephen; Koudstaal, Peter J; Sutton, George; van Dalen, Frederik J; Poole-Wilson, Philip A.

Affiliation

Kirwan BA; SOCAR Research, PO Box 2564, CH-1260 Nyon, Switzerland.

Contemp Clin Trials ; 28(6): 720-9, 2007 Nov.

Article in En | MEDLINE | ID: mdl-17509947

Subject(s)

Coronary Artery Disease/drug therapy; Sentinel Surveillance; Adult; Humans; Nifedipine/administration & dosage; Nifedipine/pharmacology; Nifedipine/therapeutic use; Placebos; Treatment Outcome; Vasodilator Agents/administration & dosage; Vasodilator Agents/pharmacology; Vasodilator Agents/therapeutic use

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Coronary Artery Disease / Sentinel Surveillance Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Humans Language: En Journal: Contemp Clin Trials Journal subject: MEDICINA / TERAPEUTICA Year: 2007 Type: Article Affiliation country: Switzerland

Search on Google

Add to My VHL

XML

PubMed Links